RA0353

antibody from Oursmab

Targeting: IL18 IGIF, IL-18, IL-1g, IL1F4

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0353

Provider

Oursmab

Product name

Camoteskimab (Biosimilar Reference Antibody) (IL18)

Antibody type

Monoclonal

Description

Camoteskimab (also known as MEDI-8999) is a humanized monoclonal antibody of the IgG1 isotype. It is designed as an antagonist to selectively target and neutralize the Interleukin-18 (IL-18) cytokine. IL-18 is a potent pro-inflammatory cytokine and a member of the IL-1 superfamily. By binding to and sequestering circulating IL-18, Camoteskimab prevents the cytokine from engaging its receptor complex, thereby inhibiting IL-18 driven inflammation. The primary goal of this inhibition is to suppress the production of other inflammatory mediators, particularly Interferon-gamma (IFN-gamma), which is downstream of IL-18 signaling. Camoteskimab has been investigated for the treatment of various inflammatory and autoimmune diseases where IL-18 signaling is implicated, such as Still's disease.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.